Clinical Trial Update: STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial compares STRIDE (durvalumab plus tremelimumab) with lenvatinib versus STRIDE alone in unresectable hepatocellular carcinoma; recruitment is o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• LENVIMA (lenvatinib)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING